Fatih Tastekin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatih Tastekin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Duygu Kerim
Department of Internal Medicine, Division of Rheumatology Ege University Faculty of Medicine Izmir Turkey
3 shared publications Kenan Aksu
3 shared publications- Figen Yargucu Zihni
Ege Univ, Fac Med, Dept Internal Med, Div Rheumatol, Izmir, Turkiye
2 shared publications - Gonca Karabulut
Ege Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı
2 shared publications - Meltem Işıkgöz Taşbakan
Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Türkiye
2 shared publications - Sait Sen
Department of Pathology, Faculty of Medicine, Ege University, Bornova, Izmir, 35100, Türkiye
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice
Objective: The biomarker potential of CD4+ T-cell subsets [naive, regulatory (Treg), inflammation-related cells (IRC)] in patients with rheumatoid arthritis (RA) has been described. This article investigates the dynamic changes in these biomarkers across the RA disease continuum from at-risk to drug-induced remission. Methods: T-cell subset biomarker data were acquired using flow cytometry. Multiple group comparisons were performed using ANOVA test (with Bonferroni correction). Results: In individuals at risk of RA, longitudinal analysis showed that IRC frequencies increased just prior to onset of clinical synovitis, while naive T-cell frequencies reduced in those progressing to clinical synovitis, but increased in non-progressors. The use of naive/IRC data improved the accuracy of RA classification, especially in ACPA-negative patients. A distinct T-cell biomarker signature was observed in late-onset RA (>60 years old vs <59). In untreated RA, the predictive value of naive T-cell frequencies for methotrexate response was confirmed. For patients on methotrexate, naive T cells increased only between 6 and 12 months and only when in remission. IRC and Treg showed no consistent change. In patients treated with TNF inhibitors, naive T-cell frequency increased independently of response, whilst sustained IRC reductions and Treg increases were seen in remission. Once in stable clinical remission, only naive frequencies increased with the length of remission on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), whilst only Treg increased over time in TNF inhibitor-induced remission. Conclusion: These studies validated that T-cell subset measurements are independent from other currently used biomarkers, highlighting differences in the impact of drug modes of action on the three T-cell subsets. There is still an unmet need for biomarkers to predict response to TNF inhibition in early RA.
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessT-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice
Objective: The biomarker potential of CD4+ T-cell subsets [naive, regulatory (Treg), inflammation-related cells (IRC)] in patients with rheumatoid arthritis (RA) has been described. This article investigates the dynamic changes in these biomarkers across the RA disease continuum from at-risk to drug-induced remission. Methods: T-cell subset biomarker data were acquired using flow cytometry. Multiple group comparisons were performed using ANOVA test (with Bonferroni correction). Results: In individuals at risk of RA, longitudinal analysis showed that IRC frequencies increased just prior to onset of clinical synovitis, while naive T-cell frequencies reduced in those progressing to clinical synovitis, but increased in non-progressors. The use of naive/IRC data improved the accuracy of RA classification, especially in ACPA-negative patients. A distinct T-cell biomarker signature was observed in late-onset RA (>60 years old vs <59). In untreated RA, the predictive value of naive T-cell frequencies for methotrexate response was confirmed. For patients on methotrexate, naive T cells increased only between 6 and 12 months and only when in remission. IRC and Treg showed no consistent change. In patients treated with TNF inhibitors, naive T-cell frequency increased independently of response, whilst sustained IRC reductions and Treg increases were seen in remission. Once in stable clinical remission, only naive frequencies increased with the length of remission on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), whilst only Treg increased over time in TNF inhibitor-induced remission. Conclusion: These studies validated that T-cell subset measurements are independent from other currently used biomarkers, highlighting differences in the impact of drug modes of action on the three T-cell subsets. There is still an unmet need for biomarkers to predict response to TNF inhibition in early RA.
- Open Access
- 27 October 2025
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
Retroperitoneal fibrosis: Features of patients followed-up by a single tertiary rheumatology center
Retroperitoneal fibrosis: Features of patients followed-up by a single tertiary rheumatology center - Journal of Turkish Society for Rheumatology
- 27 October 2025
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
Open AccessRetroperitoneal fibrosis: Features of patients followed-up by a single tertiary rheumatology center
Retroperitoneal fibrosis: Features of patients followed-up by a single tertiary rheumatology center - Journal of Turkish Society for Rheumatology
- Open Access
- 3 June 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 133 (11) , 1422-1430
Association of the energy-adjusted dietary inflammatory index and Sjögren’s syndrome: a cross-sectional study
There are no studies in the literature examining the inflammatory content and effects of the diets of patients with primary Sjögren’s syndrome (PSS). This study aimed to investigate the relationship between the Energy-Adjusted Dietary Inflammatory Index (E-DII) and anthropometric measurements, disease activity, inflammatory markers, and blood lipid concentrations in female patients with PSS. A cross-sectional study was conducted between November 2020 and November 2021, including 102 female patients with a confirmed diagnosis of PSS. Dietary intake was assessed using the multiple-pass, 3-day food record method to calculate E-DII scores. Physical activity was evaluated using the International Physical Activity Questionnaire (Short Form), anthropometric measurements were taken, and the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was used to determine disease activity. Lipid profile and inflammatory markers were analyzed in blood samples. Patients had a median E-DII value of –2·36. An anti-inflammatory diet was associated with lower anthropometric measurements and reduced total cholesterol, triglycerides, and low-density lipoprotein cholesterol concentrations. Logistic regression analysis revealed a significant association between E-DII and complement C3 (OR: 1·03, 95 % CI: 1·00, 1·05, P = 0·021) and C4 (OR: 1·08, 95 % CI: 1·01, 1·13, P = 0·019) after adjusting for age, disease score, drug use for SS, smoking, and physical activity. However, no significant correlation was found between E-DII and ESSDAI scores, C-reactive protein, or erythrocyte sedimentation rate. In conclusion, a pro-inflammatory diet was associated with higher anthropometric measurements and adverse lipid profiles in PSS patients, but its relationship with disease activity and inflammation remains unclear.
- 3 June 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 133 (11) , 1422-1430
Open AccessAssociation of the energy-adjusted dietary inflammatory index and Sjögren’s syndrome: a cross-sectional study
There are no studies in the literature examining the inflammatory content and effects of the diets of patients with primary Sjögren’s syndrome (PSS). This study aimed to investigate the relationship between the Energy-Adjusted Dietary Inflammatory Index (E-DII) and anthropometric measurements, disease activity, inflammatory markers, and blood lipid concentrations in female patients with PSS. A cross-sectional study was conducted between November 2020 and November 2021, including 102 female patients with a confirmed diagnosis of PSS. Dietary intake was assessed using the multiple-pass, 3-day food record method to calculate E-DII scores. Physical activity was evaluated using the International Physical Activity Questionnaire (Short Form), anthropometric measurements were taken, and the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was used to determine disease activity. Lipid profile and inflammatory markers were analyzed in blood samples. Patients had a median E-DII value of –2·36. An anti-inflammatory diet was associated with lower anthropometric measurements and reduced total cholesterol, triglycerides, and low-density lipoprotein cholesterol concentrations. Logistic regression analysis revealed a significant association between E-DII and complement C3 (OR: 1·03, 95 % CI: 1·00, 1·05, P = 0·021) and C4 (OR: 1·08, 95 % CI: 1·01, 1·13, P = 0·019) after adjusting for age, disease score, drug use for SS, smoking, and physical activity. However, no significant correlation was found between E-DII and ESSDAI scores, C-reactive protein, or erythrocyte sedimentation rate. In conclusion, a pro-inflammatory diet was associated with higher anthropometric measurements and adverse lipid profiles in PSS patients, but its relationship with disease activity and inflammation remains unclear.
- 10 October 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (8) , 452-453
Adalimumab treatment of resistant chondrocalcinosis
- 10 October 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (8) , 452-453
Adalimumab treatment of resistant chondrocalcinosis
- 20 July 2024
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (8) , 452-453
Adalimumab treatment of resistant chondrocalcinosis
- 20 July 2024
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (8) , 452-453
Adalimumab treatment of resistant chondrocalcinosis
- 8 July 2024
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 88 (2) , 289-296
Increased platelet-leucocyte complexes do not result in coagulation activation in plateletpheresis donors
BACKGROUND: Although plateletpheresis donation is commonly accepted as a safe procedure, its influence on platelet function, coagulation system and fibrinolysis is not completely elucidated. OBJECTIVES: In this study, we tried to assess the effects of plateletpheresis on donor’s hemostasis system by measuring platelet activation, development of platelet-leukocyte aggregates, and coagulation activation. STUDY DESIGN: Prospective observational study. METHODS: We used flow cytometry to determine the levels of platelet-monocyte complexes (PMC) and platelet-neutrophil complexes (PNC). sP-selectin and prothrombin fragment (PF) 1 + 2 values were determined by ELISA. RESULTS: The PMC levels increased significantly seven days after apheresis in comparison with just after apheresis and 24 h after apheresis ( p < 0.05). The PNC levels increased significantly seven days after apheresis compared to immediately after apheresis ( p < 0.05). sP-selectin values decreased significantly immediately after apheresis ( p < 0.05). While sP-selectin values increased seven days after apheresis in comparison with immediately after apheresis and 24 h after apheresis, but there were not statistically significant differences for sP-selectin levels ( p > 0.05). PF1 + 2 levels decreased significantly immediately after apheresis compared to pre-apheresis ( p < 0.05) and increased 24 h after apheresis and seven days after apheresis, but these differences were not statistically significant. CONCLUSION: We concluded that plateletpheresis affects platelet activation but does not cause any change in coagulation activation.
- 8 July 2024
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 88 (2) , 289-296
Increased platelet-leucocyte complexes do not result in coagulation activation in plateletpheresis donors
BACKGROUND: Although plateletpheresis donation is commonly accepted as a safe procedure, its influence on platelet function, coagulation system and fibrinolysis is not completely elucidated. OBJECTIVES: In this study, we tried to assess the effects of plateletpheresis on donor’s hemostasis system by measuring platelet activation, development of platelet-leukocyte aggregates, and coagulation activation. STUDY DESIGN: Prospective observational study. METHODS: We used flow cytometry to determine the levels of platelet-monocyte complexes (PMC) and platelet-neutrophil complexes (PNC). sP-selectin and prothrombin fragment (PF) 1 + 2 values were determined by ELISA. RESULTS: The PMC levels increased significantly seven days after apheresis in comparison with just after apheresis and 24 h after apheresis ( p < 0.05). The PNC levels increased significantly seven days after apheresis compared to immediately after apheresis ( p < 0.05). sP-selectin values decreased significantly immediately after apheresis ( p < 0.05). While sP-selectin values increased seven days after apheresis in comparison with immediately after apheresis and 24 h after apheresis, but there were not statistically significant differences for sP-selectin levels ( p > 0.05). PF1 + 2 levels decreased significantly immediately after apheresis compared to pre-apheresis ( p < 0.05) and increased 24 h after apheresis and seven days after apheresis, but these differences were not statistically significant. CONCLUSION: We concluded that plateletpheresis affects platelet activation but does not cause any change in coagulation activation.
- Open Access
- 1 July 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 2981-2991
How Do Exercise, Sleep and Depression Affect Disease Scores and Quality of Life in Primary Sjögren’s Syndrome Patients?
Purpose: Primary Sjögren’s syndrome (PSS) has many effects such as fatigue, pain, physical activity limitation and sleep disturbance, which limit patient’s daily and social lives. The aim of our study was to assess fatigue, depression, physical activity status and quality of life in patients with PSS, and to determine the relationship between these data and disease-related parameters. Patients and Methods: This study was conducted with 117 primary Sjögren’s syndrome patients. Demographic and anthropometric characteristics, disease activity (ESSDAI), quality of life scale (SF36), depression (Beck Depression Scale), physical activity status (International Physical Activity Questionnaire Short Form (IPAQ) score) and sleep status (Pittsburgh Sleep Quality Scale) of PSS patients were evaluated and relationships have been examined. Results: According to the results of our study, we found that sleep disorders are common in PSS patients (74.4%). Overweight patients, particularly higher lean mass sleep better (r:-0.201, p:0.043). Poor sleep causes fatigue (p=0.062) and depression (p=0.030). Sleep disturbance could not be explained by depressive state alone. However, after controlling for depression, the effect of sleep on fatigue seriously decreases (p=0.311). Exercise did not improve sleep quality (p=0.35) and the rate of poor sleep was higher among who exercised (p=0.192). Conclusion: Based on the results of our study, we believe that, treating depression in PSS patients is crucial for reducing fatigue. Patients need education on performing the correct exercises and weight gain should done in a professional manner. Gaining a deeper understanding of the multisystem involvement of the disease and the impact of exercise on the disease, will have positive effects on patient care and treatment decisions.
- 1 July 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 2981-2991
Open AccessHow Do Exercise, Sleep and Depression Affect Disease Scores and Quality of Life in Primary Sjögren’s Syndrome Patients?
Purpose: Primary Sjögren’s syndrome (PSS) has many effects such as fatigue, pain, physical activity limitation and sleep disturbance, which limit patient’s daily and social lives. The aim of our study was to assess fatigue, depression, physical activity status and quality of life in patients with PSS, and to determine the relationship between these data and disease-related parameters. Patients and Methods: This study was conducted with 117 primary Sjögren’s syndrome patients. Demographic and anthropometric characteristics, disease activity (ESSDAI), quality of life scale (SF36), depression (Beck Depression Scale), physical activity status (International Physical Activity Questionnaire Short Form (IPAQ) score) and sleep status (Pittsburgh Sleep Quality Scale) of PSS patients were evaluated and relationships have been examined. Results: According to the results of our study, we found that sleep disorders are common in PSS patients (74.4%). Overweight patients, particularly higher lean mass sleep better (r:-0.201, p:0.043). Poor sleep causes fatigue (p=0.062) and depression (p=0.030). Sleep disturbance could not be explained by depressive state alone. However, after controlling for depression, the effect of sleep on fatigue seriously decreases (p=0.311). Exercise did not improve sleep quality (p=0.35) and the rate of poor sleep was higher among who exercised (p=0.192). Conclusion: Based on the results of our study, we believe that, treating depression in PSS patients is crucial for reducing fatigue. Patients need education on performing the correct exercises and weight gain should done in a professional manner. Gaining a deeper understanding of the multisystem involvement of the disease and the impact of exercise on the disease, will have positive effects on patient care and treatment decisions.
- 28 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
A rare cause of AA amyloidosis: Glomus tumor and treatment with anakinra—Case report and literature review
Systemic AA amyloidosis is associated with poorly controlled chronic inflammatory disorders. Chronic infections and inflammatory arthritis are the most common causes; however, they can also rarely occur as a complication of neoplastic disorders. The development of AA amyloidosis secondary to paraganglioma, which is a rare type of tumor, has rarely been reported in the literature. In this case, an 85‐year‐old female patient with a glomus tumor in the neck, who has been followed up over 50 years, applied with complaints of loss of appetite, nausea, and diarrhea for 5–6 months. While evaluating the patient, who had high levels of acute phase reactants, amyloidosis was diagnosed by salivary gland biopsy. No other cause was found to explain amyloidosis. The patient, who could not tolerate treatment with colchicine and azathioprine, is successfully treated with the interleukin‐1 inhibitor anakinra. A rare relationship, systemic AA amyloidosis, which is thought to have developed as a result of long‐standing jugular paraganglioma, is presented in this article. In addition, publications showing an association between paragangliomas and amyloidosis were reviewed.
- 28 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
A rare cause of AA amyloidosis: Glomus tumor and treatment with anakinra—Case report and literature review
Systemic AA amyloidosis is associated with poorly controlled chronic inflammatory disorders. Chronic infections and inflammatory arthritis are the most common causes; however, they can also rarely occur as a complication of neoplastic disorders. The development of AA amyloidosis secondary to paraganglioma, which is a rare type of tumor, has rarely been reported in the literature. In this case, an 85‐year‐old female patient with a glomus tumor in the neck, who has been followed up over 50 years, applied with complaints of loss of appetite, nausea, and diarrhea for 5–6 months. While evaluating the patient, who had high levels of acute phase reactants, amyloidosis was diagnosed by salivary gland biopsy. No other cause was found to explain amyloidosis. The patient, who could not tolerate treatment with colchicine and azathioprine, is successfully treated with the interleukin‐1 inhibitor anakinra. A rare relationship, systemic AA amyloidosis, which is thought to have developed as a result of long‐standing jugular paraganglioma, is presented in this article. In addition, publications showing an association between paragangliomas and amyloidosis were reviewed.
- Open Access
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 419-428
Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases
Objectives: In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs). Patients and methods: This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines. Results: Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs. Conclusion: Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 419-428
Open AccessEfficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases
Objectives: In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs). Patients and methods: This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines. Results: Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs. Conclusion: Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.
- 16 August 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 147-150
Dermatomiyozit ayırıcı tanısında Fasiyo-Skapulo-Humeral Musküler Distrofi olgusu
- 16 August 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 147-150
Dermatomiyozit ayırıcı tanısında Fasiyo-Skapulo-Humeral Musküler Distrofi olgusu